New MS drug aims to stop disease in its tracks

NCT ID NCT05084638

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether starting a monthly injection called ofatumumab right after an MS diagnosis could help control the disease. It involved 119 adults newly diagnosed with relapsing-remitting MS and 61 healthy people for comparison. Researchers tracked participants for 18 months using brain scans, wearable devices, and clinical exams to see if the treatment could eliminate signs of active disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Arizona Neuroscience Research LLC

Phoenix, Arizona, 85032, United States
Barrow Neurological Clinics at St Josephs Hospital and MC

Phoenix, Arizona, 85013, United States
Caribbean Center for Clinical Research, Inc

Guaynabo, 00968, Puerto Rico
Emerald Coast Neurology

Pensacola, Florida, 32514, United States
Evergreen Health Multiple Sclerosis Center

Kirkland, Washington, 98034, United States
First Choice Neurology

Boca Raton, Florida, 33486, United States
Henry Ford Hospital

Detroit, Michigan, 48202-2689, United States
Keck School of Medicine

Los Angeles, California, 90033, United States
Lonestar Neurology of San Antonio

San Antonio, Texas, 78258, United States
Lundquist Inst BioMed at Harbor

Torrance, California, 90509-2910, United States
MD First Research

Chandler, Arizona, 85226, United States
MedStar Health

Washington D.C., District of Columbia, 20007, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
MultiCare Neuroscience Center of Washington

Tacoma, Washington, 98405, United States
Multiple Sclerosis Center of Excellence of OMRF

Oklahoma City, Oklahoma, 73104, United States
Neurology Associates PA

Maitland, Florida, 32751, United States
Neurology Diagnostics Inc

Dayton, Ohio, 45408, United States
Neurology of Central FL Res Ctr

Altamonte Springs, Florida, 32714, United States
Neuroscience Institute at Hackensack

Hackensack, New Jersey, 07601, United States
Ochsner Cancer Institute

New Orleans, Louisiana, 70121, United States
Orlando Health Clinical Trials

Orlando, Florida, 32806, United States
Regina Berkovich MD PhD Inc

West Hollywood, California, 90048, United States
Renown Institute for Neurosciences

Reno, Nevada, 89521, United States
Shepherd Center

Atlanta, Georgia, 30309, United States
Sibyl Wray MD Neurology PC

Knoxville, Tennessee, 37922, United States
Tallahassee Neurological Clinic

Tallahassee, Florida, 32308, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107-5098, United States
UC Health Neuroscience Ctr

Aurora, Colorado, 80045, United States
UT Health Science Center

Houston, Texas, 77030, United States
Univ of Texas Southwest Med Center

Dallas, Texas, 75390-9034, United States
University Of South Florida

Tampa, Florida, 33612, United States
University of Florida

Gainesville, Florida, 32610, United States
University of Massachusetts Medical School

Worcester, Massachusetts, 01655, United States
University of New Mexico

Albuquerque, New Mexico, 87131-0001, United States
Velocity Clinical Research

Raleigh, North Carolina, 27607, United States
West Virginia University Hospital

Morgantown, West Virginia, 26506, United States

Conditions

Explore the condition pages connected to this study.

RELAPSE REMITTING MULTIPLE SCLEROSIS